Accession Number : ADA433996


Title :   Prevention of Post-Radiotherapy Failure in Prostate Cancer by Vitamin D


Descriptive Note : Annual rept. 1 Mar 2004-28 Feb 2005


Corporate Author : CALIFORNIA UNIV DAVIS


Personal Author(s) : Vijayakumar, Srinivasan


Full Text : http://www.dtic.mil/dtic/tr/fulltext/u2/a433996.pdf


Report Date : Mar 2005


Pagination or Media Count : 112


Abstract : Prostate cancer patients receive either surgery or radiation therapy as treatment for cancer. Among patients receiving radiation therapy, nearly 50% have an elevation of PSA within five years of treatment. These patients then receive hormone treatment. In this study, we wish to test the theory that chemopreventive agents, which show the ability to prevent or delay the growth of prostate cancer cells in the laboratory, may also prevent or delay the reappearance of prostate cancer in patients who have undergone radiation to treat their prostate cancer. We propose to have prostate cancer patients who have already undergone radiation treatment take a non-toxic chemopreventive agent A SYNTHETIC FORM OF VITAMIN D, 1alpha-hydroxyvitamin D5 for two years and see if their reoccurrence rate can be decreased. Unlike regular vitamin D, D5 does not make calcium in the bloodstream reach levels that cause serious side effects. Forty patients will participate. They will be randomized to D5 or placebo arms. A biopsy will be done at the end of the study and the tissue will be analyzed for any benefit of D5 in decreasing the recurrence of prostate cancer and also for any difference between the groups in terms of expressed intermediate molecular biomarkers.


Descriptors :   *VITAMIN D , *RADIOTHERAPY , *PROSTATE CANCER , HORMONES , FAILURE , PATIENTS , CELLS(BIOLOGY) , PREVENTIVE MEDICINE , BIOPSY


Subject Categories : Biochemistry
      Medicine and Medical Research
      Radiobiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE